SYDNEY, AUSTRALIA: BCAL Diagnostics Limited announced the appointment of experienced life science and healthcare executive Dr John Hurrell as its Chief Executive Officer (CEO).
Dr Hurrell has developed and successfully commercialized multiple products and services in life sciences and diagnostics over a career in the industry spanning more than 35 years. He has developed and managed start-up and early -stage companies including succ essful life science companies based on university -developed technologies.
Most notably Dr John Hurrell spent almost 7 years in managerial and executive roles with NYSE-listed, Fortune 500 clinical laboratory company Quest Diagnostics.
Within Quest’s subsidiary Focus Diagnostics, he led the development and launch of more than 70 molecular diagnostics tests and successfully gained 510(k) approvals for 6 products. He also served as VP of Business Development at Quest Diagnostics.
Most recently, he was Chief Commercial Officer at JanaCare, a remote chronic disease patient management company with a focus on diabetes and kidney disease.
Other previous roles include President of the Asia/Pacific region and Head of International Sales for PTS Diagnostics, a diabetes and wellness company based in Indiana, USA, and Senior Executive Vice President International Business for Seegene Inc., a multinational molecular diagnostics company focusing on infectious disease, based in Seoul, South Korea.
BCAL Executive Chair Jayne Shaw commented: “We are excited to appoint a candidate as experienced and suitably skilled as John to the Chief Executive Officer role.
He has a strong track record in starting, building and improving the profitability, performance and value of life scienc e and healthcare companies, demonstrated by his many years across international roles.
We believe this will be ideal for BCAL as we continue to drive development of our technology to provide early and accurate breast cancer diagnosis to improve outcomes for patients.”
Incoming BCAL CEO Dr Hurrell said: “BCAL’s vision to develop a non-invasive blood test for the detection of breast cancer has seen extensive research and investment over the past decade and I am thrilled to be joining the company as it aims to achieve Australian and ultimately US regulatory approval for its technology, in addition to other territories. It has the potential to provide early detection of breast cancer, a disease that saw more than 2 million diagnoses in 2020, and I look forward to bringing my extensive skillset and experience in the industry to help BCAL achieve its long-term goals.”